BioCentury
ARTICLE | Company News

Evotec OAI AG, Seikagaku Corp. deal

August 16, 2004 7:00 AM UTC

EVT will use its ultra high throughput screening (uHTS) technology to identify hits from its compound library that interact with Seikagaku's inflammatory disease targets. Hits will be characterized an...